www.stiripesurse.ro/comisia-europeana-autorizeaza-

The European Commission has approved Daraxonrasib, a new treatment for metastatic pancreatic cancer, for adults who have undergone prior treatment. This medication underwent accelerated regulatory procedures without compromising EU safety and efficacy standards. The European Medicines Agency (EMA) provided a positive scientific assessment in just over 100 days. Daraxonrasib addresses an unmet medical need for better treatment options and is classified as a high-priority drug. It is also undergoing a joint clinical evaluation by EU member states to assess its clinical benefits, aiming for a report by December to facilitate access across the EU.

Fact-check this story: paste the text or link into Justificat.ro and get a verdict with the sources consulted.